Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1105 participants.
Also called NCT06858878
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,105 participants
- Sponsor
- Registry
-
NCT06858878
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Bulgaria, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Puerto Rico, South Korea, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06858878. Randomized; double masking; primary purpose treatment. Start 2025-03-17 (actual); primary completion 2027-01-21 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
- Acronym
- MARITIME-2
- Condition
- Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
- Intervention (Drug)
- Maridebart cafraglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct06858878- Content hash
1b06844129c4a30057249668782dc5173dcb3569805e6e65dd5acb394c69fa2d